ANESTAGEL™

A NEW, OPIOID-FREE PAINKILLER

  • Pre-Clinical studies completed; FDA pre-IND next
  • AniGel: Multi-billion $ Veterinary Care Opportunity
  • Phase 1 Clinical Study manufacturing line underway

 

InSitu Biologics is currently in the pre-clinical stage

Invest in InSitu Biologics:
Reg A+ Offering Open

The share price remains at $8.20. We encourage prospective investors to visit our offering page to learn more about the investment opportunity.

Please initiate your investment here: 

Invest Now

Who We Are

InSitu Biologics is an emerging biotech company focusing on development of AnestaGel™, a long-lasting and long-acting non-opiate painkiller. The sustained release drug AnestaGel is expected to be used in post-operative surgical procedures. AnestaGel may be a solution in relieving pain for broken bones, cosmetic surgery, hip/knee replacements, hernia, and more.
  • AnestaGel™

    • InSitu Biologics' lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.

    • 22+ US Patents Issued, with matching OUS positions
    • Hydrogel technology licensed from Cleveland Clinic Foundation
    • Tunable, biocompatible, and pH neutral platform
    • High dose drug-load reservoir capacity with a predictable pharmacological effect
    • Non-opioid pain relief option

    Latest News & Updates

    Pre-Clinical Results

    As compared to EXPAREL (Pacira, Inc.), the industry leading post-operative pain treatment.

    300% Longer

    Initial animal study revealed AnestaGel™ lasted up to 300% longer

    8x More Capacity

    AnestaGel™ carried 8 times more payload

    72+ Hours

    AnestaGel™ had full nerve block beyond 72 hours

    See our study at the Journal of Pain Research

    Timeline

    • 2016

      Q1
      Filed additional patent(s)

      Q2
      White Paper published

      Q3
      Completed maximum dosing study with no toxicity

      Q4
      Presented at PODD-Boston

    • 2017

      Q1
      Completed first GLP study

      Q2
      Proved more pain relief compared to Exparel in pre-clinical study

      Q3
      GLP publication accepted

      Q4
      Raised over $400k

    • 2018

      Q1
      Completed Financial Audit
      Converted all debt
      Filed $10,000,000 RegA+ Offering

      Q2
      Launch RegA+ Offering
      Announce GLP Paper by Hutchins & Taylor

      Q3
      Begin Phase 1 program manufacturing

      Q4
      Announce final GLP Study results

    • 2019

      Q1
      SEC valuation incorporating Animal Care Market opportunity

      Q2
      Submit GLP results for Peer-Review

      Q3
      FDA Pre-IND meeting

      Q4
      Expect approval for Phase 1 Clinical Study of AnestaGel